No association between bone mass and prolactin levels among patients with schizophrenia

Human Psychopharmacology

Volumn 26, Issue 8, 2011, Pages 596-601

  Sugawara, Norio ^a   Yasui Furukori, Norio ^b   Fujii, Akira ^b   Saito, Manabu ^b   Sato, Yasushi ^a,b   Nakagami, Taku ^c   Tsuchimine, Shoko ^b   Kaneko, Sunao ^b  

^a Hirosaki Aiseikai Hospital   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Odate Municipal General Hospital   (Japan)

Author keywords

bone mineral density; prolactin; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; ESTRADIOL; OLANZAPINE; PROLACTIN; QUETIAPINE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; CALCANEUS; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HORMONE DETERMINATION; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SOUND TRANSMISSION; VELOCITY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROLACTIN; SCHIZOPHRENIA;

EID: 83855163561     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1250     Document Type: Article

References (37)

1. Abraham G, Friedman RH, Verghese C, de Leon J,. 1995. Osteoporosis and schizophrenia: can we limit known risk factors? Biol Psychiatry 38: 131-132.
2. Abraham G, Halbreich U, Friedman RH, Josiassen RC,. 2003a. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 59: 17-18.
3. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC,. 2003b. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 160: 1618-1620.
4. Baastrup PC, Christiansen C, Transbøl I,. 1980. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 6: 56-59.
5. Canuso CM, Goldstein JM, Wojcik J, et al,. 2002. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 111: 11-20.
6. Castle D, Wessely S, Der G, Murray RM,. 1991. The incidence of operationally defined schizophrenia in Camberwell, 1965-84. Br J Psychiatry 159: 790-794.
7. Cetin A, Erturk H, Celiker R, Sivri A, Hascelik Z,. 2001. The role of quantitative ultrasound in predicting osteoporosis defined by dual X-ray absorptiometry. Rheumatol Int 20: 55-59.
8. Cummings SR, Rubin SM, Black D,. 1990. The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop Relat Res 252: 163-166.
9. Dane C, Dane B, Cetin A, Erginbas M,. 2008. The role of quantitative ultrasound in predicting osteoporosis defined by dual-energy X-ray absorptiometry in pre- and postmenopausal women. Climacteric 11: 296-303.
10. Dugan AL, Schwemberger S, Noel GJ, Babcock GF, Ogle CK, Buckley DJ,. 2007. Stress and prolactin effects on bone marrow myeloid cells, serum chemokine and serum glucocorticoid levels in mice. Neuroimmunomodulation 14: 287-296.
11. Frost ML, Blake GM, Fogelman I,. 2002. A comparison of fracture discrimination using calcaneal quantitative ultrasound and dual X-ray absorptiometry in women with a history of fracture at sites other than the spine and hip. Calcif Tissue Int 71: 207-211.
12. Greenspan SL, Cheng S, Miller PD, Orwoll ES,. 2001. Clinical performance of a highly portable, scanning calcaneal ultrasonometer. Osteoporos Int 12: 391-398.
13. Haddad PM, Wieck A,. 2004. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs 64: 2291-2314.
14. Halbreich U., 2007. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs 21: 641-657.
15. Halbreich U, Palter S,. 1996. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 22: 447-454.
16. Herd RJ, Blake GM, Miller CG, Parker JC, Fogelman I,. 1994. The ultrasonic assessment of osteopenia as defined by dual X-ray absorptiometry. Br J Radiol 67: 631-635.
17. Howard L, Kirkwood G, Leese M,. 2007. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190: 129-134.
18. Howes OD, Wheeler MJ, Meaney AM, et al,. 2005. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol 25: 259-261.
19. Hummer M, Malik P, Gasser RW, et al,. 2005. Osteoporosis in patients with schizophrenia. Am J Psychiatry 162: 162-167.
20. Inagaki A, Inada T,. 2008. Dose equivalence of novel antipsychotics. Part 5. Jpn J Clin Psychopharmacol 11: 887-890 (in Japanese).
21. Kamei T, Aoyagi K, Matsumoto T, et al,. 1999. Age-related bone loss: relationship between age and regional bone mineral density. Tohoku J Exp Med 187: 141-147.
22. Kang C, Speller R,. 1998. Comparison of ultrasound and dual energy X-ray absorptiometry measurements in the calcaneus. Br J Radiol 71: 861-867.
23. Lean M, De Smedt G,. 2004. Schizophrenia and osteoporosis. Int Clin Psychopharmacol 19: 31-35.
24. Lindsay R,. 1992. The effect of sex steroids on the skeleton in premenopausal women. Am J Obstet Gynecol 166: 1993-1996.
25. Liu-Seifert H, Kinon BJ, Ahl J, Lamberson S,. 2004. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics. Ann N Y Acad Sci 1032: 297-298.
26. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V,. 2004. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184: 503-508.
27. Meszaros S, Toth E, Ferencz V, Csupor E, Hosszu E, Horvath C,. 2007. Calcaneous quantitative ultrasound measurements predicts vertebral fractures in idiopathic male osteoporosis. Joint Bone Spine 74: 79-84.
28. Mulleman D, Legroux-Gerot I, Duquesnoy B, Marchandise X, Delcambre B, Cortet B,. 2002. Quantitative ultrasound of bone in male osteoporosis. Osteoporos Int 13: 388-393.
29. Nakagi Y, Ito T, Hirooka K, et al,. 2010. Association between lifestyle habits and bone mineral density in Japanese juveniles. Environ Health Prev Med 15: 222-228.
30. Nakamura K, Nashimoto M, Tsuchiya Y, Obata A, Miyanishi K, Yamamoto M,. 2001. Vitamin D insufficiency in Japanese female college students: a preliminary report. Int J Vitam Nutr Res 71: 302-305.
31. O'Keane V, Meaney AM,. 2005. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25: 26-31.
32. Opotowsky AR, Bilezikian JP,. 2003. Racial differences in the effect of early milk consumption on peak and postmenopausal bone mineral density. J Bone Miner Res 18: 1978-1988.
33. Renn JH, Yang NP, Chueh CM, Lin CY, Lan TH, Chou P,. 2009. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 10: 1.
34. Renn JH, Yang NP, Chou P,. 2010. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord 11: 35.
35. Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpuntakit J,. 2008. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 42: 535-546.
36. Tsuda-Futami E, Hans D, Njeh CF, et al,. 1999. An evaluation of a new gel-coupled ultrasound device for the quantitative assessment of bone. Br J Radiol 72: 691-700.
37. Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S,. 2002. Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology 162: 63-66.